Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

Journal of Clinical Oncology

Volumn 30, Issue 26, 2012, Pages 3209-3216

  Fischer, Kirsten ^a   Cramer, Paula ^a   Busch, Raymonde ^b   Boẗtcher, Sebastian ^d   Bahlo, Jasmin ^a   Schubert, Jöerg ^e   Pflüger, Karl H ^f   Schott, Silke ^a   Goede, Valentin ^a   Isfort, Susanne ^a   Von Tresckow, Julia ^a   Fink, Anna Maria ^a   Buḧler, Andreas ^g   Winkler, Dirk ^g   Kreuzer, Karl Anton ^a   Staib, Peter ^h   Ritgen, Matthias ^d   Kneba, Michael ^d   Doḧner, Hartmut ^g   Eichhorst, Barbara F ^a   Hallek, Michael ^a   Stilgenbauer, Stephan ^g   Wendtner, Clemens Martin ^a,c   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b University Hospital   (Germany)

^c Klinikum Schwabing   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^e Evangelic Hospital Hamm   (Germany)

^f Evangelical Diakonissenanstalt Bremen   (Germany)

^g UNIVERSITY HOSPITAL ULM   (Germany)

^h St Antonius Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CHROMOSOME DELETION; CHROMOSOME DELETION 11Q; CHROMOSOME DELETION 17P; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GERMANY; HEMOLYSIS; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRISOMY 12; TUMOR LYSIS SYNDROME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS;

EID: 84866531516     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.2688     Document Type: Article

References (30)

1. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111:5446-5456, 2008
2. Zenz T, Mertens D, Küppers R, et al: From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37-50, 2010
3. Dreger P, Döhne H, Ritgen M, et al: Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood 116:2438-2447, 2010
4. Gribben JG: How I treat CLL up front. Blood 115:187-197, 2010
5. Hallek M, Pflug N: State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 25:1-9, 2011
6. Catovsky D, Richards S, Matutes E, et al: Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 370:230-239, 2007 (Pubitemid 47069536)
7. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006 (Pubitemid 43156283)
8. Flinn IW, Neuberg DS, Grever MR, et al: Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 25:793-798, 2007 (Pubitemid 350002879)
9. Keating MJ, Kantarjian H, Talpaz M, et al: Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 74:19-25, 1989 (Pubitemid 19187405)
10. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005 (Pubitemid 46211313)
11. Rai KR, Peterson BL, Appelbaum FR, et al: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343:1750-1757, 2000
12. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005 (Pubitemid 46211312)
13. Robak T, Dmoszynska A, Solal-Céligny P, et al: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756-1765, 2010
14. Hallek M, Fischer K, Fingerle-Rowson G, et al: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet 376:1164-1174, 2010
15. Ozegowski W, Krebs D: W-[bis-(chlorethyl)-amino-benzimidazolyl-(2)]- propionic or butyric acids as potential cytostatic agents. J Prakt Chem 20:178-186, 1963
16. Ozegowski W, Krebs D: IMET 3393, gamma-(1-methyl-5-bis-(β- chloräthyl)-amino-benzimidazolyl(2)-buttersäure-hydrochlorid, ein neues Zytostatikum aus der Reihe der Benzimidazol-Loste [in German]. Zbl Pharm 110:1013-1019, 1971
17. Hartmann M, Zimmer C: Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 287:386-389, 1972
18. Cheson BD, Wendtner CM, Pieper A, et al: Optimal use of bendamustine in chronic lymphocytic leukemia, non-Hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel. Clin Lymphoma Myeloma Leuk 10:21-27, 2010
19. Knauf WU, Lissichkov T, Aldaoud A, et al: Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378-4384, 2009
20. Fischer K, Cramer P, Busch R, et al: Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559-3566, 2011
21. Bergmann MA, Goebeler ME, Herold M, et al: Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study Group. Haematologica 90:1357-1364, 2005 (Pubitemid 41503651)
22. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996 (Pubitemid 26189840)
23. National Cancer Institute, Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm
24. Kröber A, Seiler T, Benner A, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002 (Pubitemid 34864299)
25. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000 (Pubitemid 32064784)
26. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
27. Böttcher S, Ritgen M, Fischer K, et al: Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980-988, 2012
28. Foon KA, Boyiadzis M, Land SR, et al: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:498-503, 2009
29. Reck M, Haering B, Koschel G, et al: [Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine: A phase II study] [in German]. Pneumologie 52:570-573, 1998
30. Cheson BD, Kroll ML: Bendamustine induced neurotoxicity. Clin Adv Hematol Oncol 7:743-746, 2009